date:May 13, 2014
ially offset by unfavourable foreign exchange impacts. In the quarter, the company received the required regulatory approvals for its new Seal Sands, U.K., plant and began commercial sales of new pharmaceutical grade omega-3 product lines.
The company maintains its expectation of a full-year 2014 segment earnings increase of mid-teens% versus 2013 driven by higher volumes in texture and stability solutions, omega-3s, natural colours and binder product lines.
In the first quarter, the company a